Kornimate/medical-research-clean huggingface dataset:
jak-inhibition in recurrent classical hodgkin lymphoma

Conditions: Recurrent Classical Hodgkin Lymphoma

Summary: the purpose of this trial is: * to determine the overall response rate (orr, complete response \[cr\] + partial response \[pr\]) in patients with relapsed or refractory hl * to determine the safety profile of ruxolitinib in patients with relapsed or refractory hl


Eligibility criteria:
inclusion criteria: * relapsed or refractory hl * ecog \<= 2, * no major organ dysfunction * written informed consent exclusion criteria: * history of another primary malignancy ≤ 2 years * female patients who are pregnant or breast feeding * patients with a known history of hiv seropositivity * chronic active hepatitis
a novel vaccine for the treatment of muc1-expressing tumor malignancies

Conditions: Multiple Myeloma; Tumors

Summary: rationale: immucin was shown to be able to induce a robust cellular immune response mediated via both cd4+ and cd8+ t lymphocytes and therefore, could potentially be more effective in the majority of the target population. purpose: the purpose of this study is to evaluate the safety and initial efficacy of immucin, a novel peptide vaccine in metastatic tumors expressing the muc-1 tumor associated antigen (taa).


Eligibility criteria:
inclusion criteria: * all patients must have a histological or cytological diagnosis of metastatic disease expressing the muc-1. patients must have metastatic disease and have failed at least one regimen of standard based chemotherapy for metastatic disease such as: * renal cell carcinoma (rcc), * transitional cell carcinoma (tcc), * prostate, * breast, * ovary, * non-small cell lung, * colon, * multiple myeloma and * pancreatic. * patients must be \>18 years of age, consenting to participation in the study. * patients must have at least one site of measurable tumor or measurable tumor marker. exclusion criteria: * patients receiving any immunosuppressive treatment that could negate development of an effective immune response to the vaccine. * subjects with prior irradiation to a field that includes more than 25% of their lymph nodes and bone marrow likely to be immunosuppressed will be excluded. however, patients who had standard pelvic field radiation such as adjuvant therapy for rectal cancer are not excluded. * pregnant and breast feeding women will be excluded. premenopausal women who are not practicing or willing to practice adequate birth control methods for a period of 3 months after treatment will be excluded. * patients with brain metastases. * patients with active infection. * patients with hiv hepatitis b surface antigen (hbs ag) and hepatitis c virus (hcv) positive patients.

Keywords: metastatic solid tumors
extension of a study of allogeneic hematopoietic stem cell transplantation from one haplotype mismatch related donor or from an unrelated donor to younger patients eligible for reduced-intensity conditioning regimen

Conditions: Acute Leukemia; Non Hodgkin Lymphoma; Multiple Myeloma

Summary: this study is an extension to younger patients of the currently ongoing national, multicenter, open-label, randomized phase iii haplomudelderly which evaluates elderly patients with hematological malignancies, justifying an allo-hsct from an alternative donor when a mrd has not been identified. it will extend the investigation of these two modalities of allo-hsct to younger patients which are eligible to ric.


Eligibility criteria:
inclusion criteria: * patients with hematological malignancy * age\<55 years * hct-ci score ≥ 3 or non-eligible for myeloablative regimen * patients without a matched related donor * patients eligible for an allogeneic hsct from an alternative donor * able to comply with the protocol * written informed consent * patient affiliated to the national "social security" regimen or beneficiary of this regimen exclusion criteria: * clinical or biological contraindication to allogeneic hsct * pregnant or breast-feeding women. * patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up. * severe concomitant disease
single incision pelvic floor mesh implants

Conditions: Intra-operative Complications; Post Operative Complications

Summary: objectives: to evaluate whether the use of single incision un-anchored small mesh implants is feasible, safe and effective for women with moderate pelvic organ prolapse. design: patients diagnosed with moderate pelvic organ prolapse were enrolled to undergo a single incision un-anchored mesh operation. follow-up was 4 to 23 months. the outcome measures for this study were the operative safety and post-operative pain, adverse effects and anatomical as well as functional cure. setting: the operations were performed under general anesthesia according with the reported surgical techniques at university and private hospitals.

eligibility criteria: female patients with moderate pelvic organ prolapse outcome measures: intra operative safety and surgical complications, post operative complications and objective as well as subjective cure rates

Eligibility criteria:
inclusion criteria: \* patients with gr 2-3 pelvic organ prolapse exclusion criteria: \*previous pelvic irradiation

Keywords: single incision, mesh, complications
mylotarg and ara-c in untreated patients above 60 years with aml and high-risk mds

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome

Summary: the purpose of this study is to find out how safe and effective the combination of mylotarg in combination with cytarabine is in treating patients with acute myeloid leukemia and advanced myelodysplastic syndrome over the age of 60 years.

to evaluate the safety and efficacy of gemtuzumab ozogamicin in combination with cytarabine in inducing complete remission in patients with aml and advanced mds over the age of 60 years. patients eligible for treatment will receive the following: mylotarg at 6 mg/m2 on day 1 as a 2 hour intravenous infusion cytarabine at 100 mg/m2/day as a continuous intravenous infusion daily for 7 days

Eligibility criteria:
inclusion criteria: * histologic diagnosis of aml or advanced mds * no prior cytotoxic treatment for aml. (patients may have been treated with prior biologic therapy) patients with mds or aml that has evolved from mds, could have received prior low-dose cytotoxic therapy (i.e. azacytidine or low-dose ara-c). exclusion criteria: * uncontrolled or severe cardiovascular disease or pulmonary disease

Keywords: acute myeloid leukemia myelodysplastic syndrome
evaluation of fondaparinux in patients with a heart rhythm disturbance who undergo restoration of normal heart rhythm

Conditions: Fibrillation, Atrial

Summary: the purpose of this study is to test whether fondaparinux is effective and safe to prevent thromboembolic events (like for example strokes) and bleeding events in patients who undergo a normalisation of their heart rhythm disturbance. fondaparinux will be compared with heparin and tablets containing vitamin-k-antagonists (phenprocoumon, fluindione, or warfarin).


Eligibility criteria:
inclusion criteria: * male or female patients aged at least 18 years with atrial fibrillation (af) meeting at least one of the following criteria (a, b, c): a. acute clinical symptoms (like palpitations, chest pain, dyspnea, fatigue, lightheadedness, or syncope) for at least 48 hours and af on baseline ecg b. newly discovered af persisting for \>=7 days c. recurrent af persisting for \>=7 days exclusion criteria: * no documented sinus rhythm on ecg for more than 1 year * acute neurological deficits (tia, stroke, intracranial bleeding), or known disease which may cause neurological deficits (e.g., multiple sclerosis, seizure disorder) * treatment with antithrombotic agents, including low-dose anticoagulation, for more than 48 hours prior to randomisation * treatment with oral nsaids or asa at doses greater than 325 mg per day for more than 72 hours prior to randomisation * anticoagulant therapy required or likely to be required during the study period * treatment with asa at a dose greater than 325 mg per day or oral nsaids (at any dose) required or likely to be required during the study period * treatment with two or more antiplatelet agents (e.g. clopidogrel and asa) at any dose at the same time (i.e., within 24 hours) * known hypersensitivity to ufh, vka, or fondaparinux or one of these drugs' excipients * active, clinically significant bleeding or clinically significant bleeding within the past month * major surgery within the previous three months * uncontrolled arterial hypertension (persistent systolic blood pressure over 180 mm hg or diastolic blood pressure over 110 mm hg) * bacterial endocarditis * calculated creatinine clearance \< 30 ml/min * body weight \< 50 kg * planned surgery or intervention within the next 65 days

Keywords: cardioversion, electric pathological conditions, sings and symptoms cardiovascular diseases heart diseases atrial fibrillation arrhythmias, cardiac pathologic processes anticoagulants
esketamine for the treatment of rett syndrome

Conditions: Rett Syndrome

Summary: the goal of this interventional study is to learn about the efficacy and safety of esketamine for treating children with rett syndrome (rtt). the main questions it aims to answer are: * whether esketamine treatment is effective in improving symptom severity for rtt. * whether esketamine is safe in the treatment of rtt. participants will receive a weekly intravenous infusion of esketamine for five weeks and will be assessed for disease severity and drug safety.


Eligibility criteria:
inclusion criteria: * classic/typical rtt * causing mutation in mecp2 gene * stable pattern of seizures, or has had no seizures at least 8 weeks exclusion criteria: * use of other drugs that interact with esketamine: thyroxine, meglumine diatrizoate, aminophylline, diazepam or midazolam, drugs for antihypertension or central nervous depressants, halogenated general anesthetics (e.g., halothane), tubocurarine, atracurium * condition with hypertension, high cerebrospinal fluid pressure, and high intraocular pressure * unstable systemic illness other than rett syndrome: current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, type 1 diabetes, or uncontrolled type 2 diabetes), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease), or major surgery planned during the study * clinically important variations in medication use

Keywords: rett syndrome esketamine efficacy safety
otx-14-006: a phase 2 study evaluating the safety and efficacy of otx-dp for the treatment of dry eye

Conditions: Dry Eye

Summary: the objective of the study was to evaluate the efficacy and safety of otx-dp (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of dry eye disease


Eligibility criteria:
inclusion criteria: * had a known history of dry eye disease * had a minimal corneal fluorescein staining score and osdi score in each eye exclusion criteria: * history of intraocular inflammation in either eye * use of the anti-inflammatory or immunomodulating agents ocular or systemic for the duration of the study * uncontrolled glaucoma or is on medications to treat glaucoma * history of iop spikes in either eye * active epiphora
hand ligament reconstructions with knee collateral ligament allografts

Conditions: Hand Injuries; Wrist Injuries; Ligament Injury; Ligament Rupture; Ligament Avulsion

Summary: the purpose of this study is to review the clinical outcomes following hand ligament reconstruction surgery using allograft (cadaveric) knee collateral ligaments. currently, there is no standard procedure or devices used for hand ligament reconstruction surgery, although most techniques use some form of autograft (patients' own tissue) for the reconstruction. we believe that the use of allograft ligaments in reconstruction may eliminate the pain associated with procuring the patients' own tissue for the procedure, and prove to be a viable and preferred alternative to the multiple techniques currently used. the main procedures of this study include wrist and hand ligament reconstruction surgery (for wrist scapholunate (sl) ligaments, thumb ulnar collateral ligaments (ucl), and finger proximal interphalangeal (pip) joint collateral ligaments) using allograft ligament, and subsequent follow up appointments where measurements and questionnaires will be completed to evaluate how hand function is doing after surgery.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * have symptomatic injuries to either their finger pip collateral ligaments, thumb ucl ligaments, or wrist sl ligaments and have failed non-operative management for the above ligament injuries (thus eligible for operative reconstruction) * age over 18 years exclusion criteria: * presence of any other current injury in that limb * presence of advanced arthrosis in that limb * presence of fixed joint deformity in that limb * presence of instability in that limb due to bony or articular instability * presence of instability in that limb due to inflammatory arthrosis * is under 18 years of age * lacks the capacity to consent

Keywords: hand ligament injury, wrist ligament injury
clinical evaluation of bacitracin

Conditions: Allergic Contact Dermatitis

Summary: the purpose of this study is to establish a concentration of a bacitracin-patch for diagnosing allergic contact dermatitis.

thin-layer rapid use epicutaneous test (t.r.u.e. test®) is a ready-to-use patch test method designed for diagnosis of allergic contact dermatitis. the standard panel consists of two tape strips, panel 1, with 11 allergen patches and a negative control and panel 2, with 12 allergen patches. t.r.u.e. testtm panels 1 and 2 contain 23 of the most frequent contact allergens. with the 23 allergens the test currently consists of, it is possible to detect about 60-70% of contact allergic reactions. thus, there is a need for expanding the number of allergens included in t.r.u.e.test in order to detect more contact allergic reactions. bacitracin is one of these allergens, and the purpose of this study is to determine a concentration for the patch by using a bacitracin dilution series.

Eligibility criteria:
inclusion criteria: * positive bacitracin patch test within the latest 5 years. * age greater than or equal to 18 years. * signed informed consent. exclusion criteria: * topical treatment with corticosteroids or immunosuppressives during the latest 7 days on the test area or near the test area. * systemic treatment with corticosteroids or immunosuppressives during the latest 7 days. * treatment with ultraviolet (uv)-light during the latest 3 weeks. * widespread active dermatitis or dermatitis on test area. * breast-feeding or pregnancy. females of childbearing potential must demonstrate a negative pregnancy test before inclusion in the study. * subjects not able to cooperate.

Keywords: allergic contact dermatitis patch testing bacitracin
ttt versus ttt and triamcinolone to decrease exudation in choroidal melanoma after proton beam therapy

Conditions: Exudative Retinal Detachment; Uveal Melanoma

Summary: proton beam therapy is a safe irradiation modality for choroidal melanoma. but often after irradiation the exudation increases resulting in an exudative retinal detachment requiring vitreoretinal surgery. it is known that intravitreally injected triamcinolone and ttt is capable to decrease the exudation. if there is any advantage in a combined treatment this study will investigate.

proton beam therapy is an eye preserving irradiation modality for uveal melanoma. after proton beam therapy tumor related lipid exudation and exudative retinal detachment often increase. therefore vitreoretinal surgery is sometimes required to reattach the retina to protect visual acuity. it is known that intravitreally injected triamcinolone and ttt is capable to decrease exudation. if there is any advantage in a combined treatment and if it is that effective to possibly avoid vitreoretinal surgery this study will investigate.

Eligibility criteria:
inclusion criteria: •exudation (tumor associated exudation/exudative retinal detachment) after proton beam therapy in choroidal melanoma and/or ciliary body melanoma exclusion criteria: * tumor recurrence * endoresection and / or previous vitrectomy * treatment with anti-angiogenic drugs or intravitreal corticosteroids or any other investigational drug within 3 months prior to randomisation * prior laser photocoagulation treatment within 3 months (focal / grid laser) or 6 months (panretinal) prior to study entry * known hypersensitivity against local anaesthetics
long-term pantoprazole trial in patients with symptoms of chronic acid peptic complaints (by1023/vmg-708)

Conditions: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers

Summary: gastroesophageal reflux disease (gerd) is a medical condition affecting the stomach and esophagus. gerd might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. gerd is one of the most common medical disorders, with estimates of up to 50% of adults reporting reflux symptoms. one of the main symptoms of gerd is heartburn. it occurs when the acidic content from the stomach touches the lining of the esophagus, causing a burning sensation in the chest or throat. proton pump inhibitors such as pantoprazole can relieve symptoms of gerd and peptic ulcers in a large proportion of patients. additionally, long-term treatment with proton pump inhibitors may be needed for patients with chronic ulcer disease not caused by h. pylori (h. pylori is a stomach-dwelling bacteria which is often associated with ulcers in the stomach or duodenum). the aim of the study is to evaluate the long-term effect of pantoprazole in patients with chronic gastric acid-related complaints. the study duration consists of a 5-year treatment period. pantoprazole will be administered once daily. the study will provide further data on long-term safety, tolerability, and efficacy of pantoprazole.


Eligibility criteria:
main inclusion criteria: * patients who completed altana pharma study by1023/fk3006 (long-term clinical trial regarding efficacy and tolerability of pantoprazole in patients not responding to treatment with h2-receptor antagonists or omeprazole) * written informed consent main exclusion criteria: * concomitant diseases * pregnant or nursing female patients; female patients of childbearing potential who are not using reliable contraception

Keywords: gastric acid gerd gastroesophageal reflux disease pantoprazole proton pump inhibitor
study to assess medication satisfaction in patients with relapsing remitting multiple sclerosis treated with copaxone®

Conditions: Multiple Sclerosis

Summary: the primary objective of this study is to compare patient medication satisfaction as measured by the medication satisfaction questionnaire (msq) scores between the copaxone 40 mg/ml three time a week (tiw) group and the copaxone 20 mg/ml once daily (qd) group over 6 months of treatment.


Eligibility criteria:
inclusion criteria: 1. men or women at least 18 years of age or older. 2. patients must have a confirmed and documented rrms diagnosis 3. patients must be ambulatory with a kurtzke edss score of 0 to 5.5 at screening visit. 4. patients must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment 30 days prior to randomization. 5. women of child-bearing potential must have a negative urine pregnancy test at screening visit and must practice an acceptable method of birth 6. patients must be able to sign and date a written informed consent prior to entering the study. 7. patients must be willing and able to comply with the protocol requirements for the duration of the study. exclusion criteria 1. patient had any contraindication to copaxone therapy. 2. previous use of copaxone 40 mg/ml three times per week. 3. patients with progressive forms of ms. 4. patients with neuromyelitis optica. 5. use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening. 6. patients who have been treated with; immunosuppressive medications, immunoglobulins and/or monoclonal antibodies, alemtuzumab, cladribine, cyclophosphamide or mitoxantrone at any time 7. chronic (more than 30 consecutive days) systemic (iv, po or im) corticosteroid treatment within 6 months prior to screening visit. 8. pregnancy or breastfeeding. 9. clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation 10. employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals * other criteria may apply, please contact the investigator for more information
laser co2 versus tens after reconstruction of the rotator cuff

Conditions: Rotator Cuff Injury

Summary: the purpose of this study is to evaluate the most effective method between transcutaneous electrical stimulation and light amplification by stimulated emission of radiation therapy carbon dioxide therapy for pain control in the post-surgical rehabilitation of patients treated with reconstruction of the rotator cuff.

to evaluate the most effective method between transcutaneous electrical stimulation and light amplification by stimulated emission of radiation therapy carbon dioxide for pain control in the post-surgical rehabilitation of patients treated with reconstruction of the rotator cuff and to evaluate, at the end of the rehabilitation period, the range of motion, the function gained and the quality of life comparatively in the two groups of patients treated with transcutaneous electrical stimulation or light amplification by stimulated emission of radiation therapy carbon dioxide therapy.

Eligibility criteria:
inclusion criteria: * subjects after surgery for rotator cuff injury of traumatic and / or degenerative exclusion criteria: * concomitant fractures of the humerus, pace-maker, diseases for which treatments are contraindicated.

Keywords: rotator cuff surgery pain exercise therapy
the neuropsychiatric evaluation of hiv-positive and negative drug using individuals: study 215

Conditions: HIV Infections

Summary: the lack of success in treating substance abuse may be contributed to by a limited understanding of the clinical neurobiology of drug abuse. a better understanding of such deficits might aid in the development of more relevant pharmacological and psychosocial treatment approaches. thus, the purpose of this study is to test the hypothesis that repetitive illicit drug use may be associated with cortical and subcortical structural abnormalities, vascular abnormalities, as well as neuropsychological decrements. additionally, a battery of psychological tests are administered to provide information about demographics, drug use, neurocognitive measures, and personality structures....

the lack of success in treating substance abuse may be contributed to by a limited understanding of the clinical neurobiology of drug abuse. a better understanding of such deficits might aid in the development of more relevant pharmacological and psychosocial treatment approaches. thus, the purpose of this study is to test the hypothesis that repetitive illicit drug use may be associated with cortical and subcortical structural abnormalities, vascular abnormalities, as well as neuropsychological decrements. additionally, a battery of psychological tests are administered to provide information about demographics, drug use, neurocognitive measures, and personality structures.

Eligibility criteria:
* data analysis protocol

Keywords: hiv positive